Department of Error

Abstract

Park S-J, Ahn J-M, Kang D-Y, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 2024; 403: 1753–65—In table 2 of this Article, the proportion of patients in the optimal medical therapy group with target-vessel-related myocardial infarction at 4 years should have been 0·9%. This correction has been made to the online version as of Nov 14, 2024.